pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,349 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1817Endpoints1411Fierce Biotech731BioSpace719BioPharma Dive532raps241onclive165fda recalls116
therapy area
allOncology12513Rare Disease3255Immunology2927Cardiology2830Hematology2218Pulmonology2176Vaccines
  • Dana-Farber and Beth Israel Lahey Health break ground on $1.68 billion cancer hospital in Boston
    Officials from Dana-Farber Cancer Institute and Beth Israel Lahey Health announced the start of construction on a new dedicated cancer hospital in Boston's Longwood area. The project is budgeted at…
    STAT · 25d agoDealPositive↗ source
  • Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proof
    The article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
    BioPharma Dive · 25d agoNeutral↗ source
← prev
page 22 of 134
next →
fda medwatch112
globenewswire health73
fda press59
1820
Psychiatry & CNS1221
Ophthalmology1081
Endocrinology & Metabolism785
Pain784
Nephrology764
  • Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trial
    Gilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…
    BioSpace · 25d agoPositive readoutPositive↗ source
  • Midterm ballot measures spotlight abortion, transgender rights and Medicaid expansion
    Voters in the upcoming midterm elections will weigh a series of state ballot questions that address contentious health topics such as abortion access, transgender health care and the expansion of M…
    STAT · 25d agoRegulatoryNeutral↗ source
  • Lawmakers push FDA to close loophole allowing import of counterfeit Eli Lilly obesity drug
    A bipartisan group of U.S. lawmakers is urging the Food and Drug Administration to address a regulatory gap that permits the importation of unapproved versions of retatrutide, an experimental obesi…
    STAT · 25d agoRegulatoryNeutral↗ source
  • BioSpace podcast highlights Q3 job market gains and sharp layoff decline for biopharma talent
    BioSpace Vice President of Marketing Chantal Dresner and content manager Angela Gabriel released a bonus podcast episode reviewing the biopharma job market in the third quarter of 2026. They repor…
    BioSpace · 25d agoPositive↗ source
  • Proposed ACGME rule changes could strip resident doctors of mandatory rest periods
    Arifeen Rahman, a clinical instructor in rhinology at the Medical University of South Carolina, recounts working 90-hour weeks as a junior otolaryngology resident in 2023, often exceeding the ACGME…
    STAT · 25d agoRegulatoryNegative↗ source
  • BioSpace releases Q3 2026 biopharma job market report showing upbeat hiring trends
    BioSpace has published its third quarter 2026 biopharma job market report, which examines hiring activity, workforce cuts and overall employment patterns across the sector. The analysis highlights…
    BioSpace · 25d agoPositive↗ source
  • New poll gauges U.S. voter attitudes toward transgender sports participation and abortion access
    A recent assessment released by STAT examines how American voters feel about transgender youth competing in school sports and about access to abortion services. The analysis is presented as a concr…
    STAT · 25d agoNeutral↗ source
  • Nursing home cuts resident care while diverting revenue to real estate, state oversight lacking
    A Boston Globe Spotlight investigation found that a nursing home in Taunton, once praised for high quality, has seen a sharp decline in resident care after a new owner took over. The new owner, El…
    STAT · 25d agoNegative↗ source
  • JAMA paper on OpenEvidence highlights clinician use but raises unanswered questions
    A new study published in JAMA examines how clinicians are employing the OpenEvidence platform, an artificial-intelligence-driven tool designed to assist medical decision-making. The authors highli…
    STAT · 25d agoNeutral↗ source
  • Reporter urges audiences to skip new Elizabeth Holmes documentary
    Matthew Herper, a reporter covering medical innovation, recounts his two interviews with Elizabeth Holmes in 2015, at the peak of Theranos hype. The first interview occurred just before John Carre…
    STAT · 25d agoNegative↗ source
  • Roche signs $15 billion ADC partnership with China's Hansoh, offering $400 million upfront
    Roche announced a licensing agreement with Hansoh Pharmaceutical to develop a broad portfolio of antibody-drug conjugates (ADCs).\n\nThe deal includes an upfront cash payment of $400 million and a…
    BioSpace · 26d agoDealPositive↗ source
  • Roche signs up to $15 billion ADC partnership with China's Hansoh, paying $400 million upfront
    Roche announced a new partnership with Chinese drugmaker Hansoh Pharmaceutical Group focused on antibody‑drug conjugates. The agreement includes an upfront payment of $400 million and the potential…
    BioPharma Dive · 26d agoDealPositive↗ source
  • Merck KGaA to acquire Silence Therapeutics for $1.3 billion, adding Phase-2 RNAi drug for polycythemia vera
    Merck KGaA announced it will purchase UK‑based Silence Therapeutics for about $1.3 billion, paying $20 in cash per share, representing a 130 % premium. The deal gives Merck control of an RNA‑inter…
    BioPharma Dive · 26d agoDealPositive↗ source
  • Sanofi breaks ground on Frankfurt insulin API plant with €400 million German aid
    Sanofi has started construction of a new insulin active pharmaceutical ingredient (API) manufacturing facility at its Frankfurt site in Germany. The plant, covering about 36,000 square meters, is…
    BioSpace · 26d agoDealPositive↗ source
  • Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic porphyria
    Disc Medicine announced that its experimental therapy bitopertin achieved its primary and secondary goals in a Phase 3 trial for erythropoietic porphyria, a rare condition that makes patients extre…
    BioPharma Dive · 26d agoPositive readoutPositive↗ source
  • Merck KGaA to acquire Silence Therapeutics for $1.1 billion, gaining Phase 3 PV siRNA asset
    Merck KGaA announced it will buy Silence Therapeutics for about $1.1 billion, giving the German group a foothold in hematology. Silence, a UK-based RNA specialist, develops short interfering RNA m…
    BioSpace · 26d agoDealPositive↗ source
  • Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic protoporphyria, setting stage for FDA resubmission
    Disc Medicine's bitopertin, being developed for erythropoietic protoporphyria (EPP), a rare blood disorder that causes painful light sensitivity, had its accelerated FDA application rejected in Feb…
    BioSpace · 26d agoPositive readoutPositive↗ source
  • Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trial
    Gilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast. In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adju…
    STAT · 26d agoPositive readoutPositive↗ source
  • Trump signs executive order to create NIH division and White House task force for women’s health
    President Donald Trump signed an executive order on Monday establishing a new division within the National Institutes of Health and a White House task force focused on women’s health. The order dir…
    STAT · 26d agoRegulatoryNeutral↗ source
  • EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edema
    EyePoint said it is launching a strategic review after its investigational drug duravyu failed another Phase 3 study in wet age‑related macular degeneration. The company reported that the top‑line…
    BioSpace · 26d agoLayoffsNegative↗ source
  • China proposes new limits on foreign biotech acquisitions to protect domestic drug development
    China is drafting new rules that would restrict foreign companies from acquiring Chinese biotech assets deemed critical to the nation's drug development sector. The proposal aims to keep control o…
    STAT · 26d agoRegulatoryNeutral↗ source
  • FDA forms new board to guide drug exclusivity decisions as Roche reexamines German investments
    The U.S. Food and Drug Administration's Center for Drug Evaluation and Research has created a board to oversee and advise on drug exclusivity decisions. Reuters reports the board is intended to imp…
    STAT · 26d agoRegulatoryNeutral↗ source
  • Veradermics reports Phase 3 minoxidil pill boosts hair coverage in men
    After a February IPO that raised more than $256 million and a strong share rally, Connecticut‑based Veradermics now has late‑stage data for its oral minoxidil candidate. In the Phase 3 Study 304,…
    BioSpace · 26d agoPositive readoutPositive↗ source